GenomeDx Biosciences entered into a research collaboration with Astellas to apply genomic tumor profiling using GenomeDx's Decipher Classifier and Decipher GRID as a potential aid in the identification of prostate cancer patients undergoing active surveillance who may benefit from treatment with XTANDI (enzalutamide).
FDA approved the drug Imbruvica (imbrutinib) for the treatment of patients with relapsed/refractory marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy.
Merck KGaA, Darmstadt, Germany, announced a collaboration and licensing agreement with Domain Therapeutics, Strasbourg, France, to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents.
Genentech said FDA accepted the company's supplemental Biologics License Application and granted Priority Review for Tecentriq (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin chemotherapy, and are either previously untreated or have disease progression at least 12 months after receiving chemotherapy before surgery or after surgery.
ONCURIOUS NV, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors, announced that the European Commission has confirmed the orphan drug designation for TB-403 for medulloblastoma.
M2Gen said Merck has joined the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program.
The Scripps Research Institute announced a research collaboration and license agreement with Pfizer Inc. to pioneer new DNA-encoded library technology, including new synthetic chemistry for the creation of next-generation DELs, a potentially transformative technology for early stage drug discovery research.
AbbVie announced four collaborations and investments with leading healthcare innovators to advance early-stage research in key therapeutic areas such as oncology and immunology.
Eli Lilly and Co. announced the expansion of an existing immuno-oncology collaboration with to add a new study of Lilly's Lartruvo (olaratumab) with Keytruda (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma.
Amgen and Immatics Biotechnologies GmbH announced a research collaboration and exclusive license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers.